PamGene International B.V. We have developed new applications on our patented technology platform that measures cellular kinase activity as well as nuclear receptor activity broadly. This enables more understanding of drug interactions with these important classes of signalling molecules. Our technology is widely in use in support of drug R&D for elucidation of drug-target interactions and in support of clinical trials as a drug activity based biomarker platform, which is a paradigm shift from the more traditional biomarkers that only focus on presence of certain RNA, DNA or protein molecules and not their activity nor the interaction with the drug.